Trial Profile
A Phase I Study of the Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs LMB 100 (Primary) ; SEL-403 (Primary) ; Sirolimus (Primary)
- Indications Mesothelioma; Peritoneal cancer
- Focus Adverse reactions
- 04 Nov 2019 Status changed from completed to discontinued.
- 13 Jun 2019 Status changed from suspended to completed.
- 31 Dec 2018 Status changed from recruiting to suspended as Grand 5 pneumonits occurred. as Per PI and FDA enrollment is hold.